Virbac SA is one of the world's largest independent pharmaceutical companies dedicated exclusively to animal health. The company's business model centers on the research, development, manufacturing, and commercialization of veterinary medicines, vaccines, and health products for both companion animals (dogs, cats, horses) and food-producing animals (cattle, pigs, poultry, aquaculture). Virbac's product portfolio covers a wide range of therapeutic areas, including parasiticides, antibiotics, vaccines, dermatology, dentistry, and specialized pet food.
Geographically, Virbac has a highly diversified global footprint, generating revenue across Europe, North America, Latin America, Asia, and the Pacific. The company operates manufacturing sites and R&D centers internationally, allowing it to tailor its veterinary solutions to regional epidemiological needs. Revenue is primarily split between two main segments: companion animals, which account for approximately 60% of total sales, and food-producing animals, which make up the remaining 40%.
Virbac's competitive position is strengthened by its pure-play focus on veterinary medicine, its strong relationships with veterinary professionals, and a consistent strategy of targeted acquisitions, such as its recent integrations of Globion in India and Sasaeah in Japan. By continuously expanding its portfolio of vaccines and alternatives to antibiotics, Virbac addresses the growing global demand for preventative animal healthcare and sustainable farming practices.
